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Abstract
Over half of patients diagnosed with acute myeloid leukemia (AML) are 65 years or older.
Using the linked SEER-Medicare database, we conducted a retrospective cohort analysis
to examine patient characteristics, treatment patterns, and survival among the elderly
AML patients in routine clinical practice. Out of 29,857 patients with AML in the database,
8336 were eligible for inclusion in the study. The inclusion criteria included a diagnosis
with first primary AML between January 1, 2000 and December 31, 2009, >66 years of age,
and continuous enrollment in Medicare Parts A and B in the year before diagnosis. Forty
percent (N = 3327) of the cohort received chemotherapy within 3 months after diagno‐
sis. The multivariable overall survival analyses showed a lower risk of death among those
receiving intensive and hypomethylating agent therapies compared with no therapy.
Among the younger cohort, a significant lower mortality was also noted with receipt of
allogeneic hematopoietic stem cell transplantation. Over the past decade, about 60% of
the elderly AML patients remain untreated in routine clinical practice. Use of antileuke‐
mic therapy was associated with a significant survival benefit and provides further support
that age alone should not deter the use of guideline-recommended therapies particular‐
ly because of the high disparities in outcomes between treatment receipt and palliative
care in this elderly cohort.
Keywords: acute myeloid leukemia, immunotherapy, chemotherapy, elderly patients,
survival
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1. Introduction
The American Cancer Society estimates that about 20,830 new cases of acute myeloid leuke‐
mia (AML) will be diagnosed in the United States in 2015 and 10,460 people will die of the disease
[1]. Incidence of AML increases with age, with a median age at diagnosis of 66 years making it
primarily a disease of the elderly [2]. Survival rates decline with age and AML is the leading
cause of mortality from leukemia in the United States [3, 4].
The management of older adults with AML poses a difficult clinical challenge as they are more
likely to have comorbidities and poorer performance status which can limit treatment options
and tolerability. Treatment efficacy and tolerability have been shown to deteriorate markedly
with age [5]. Although intensive combination chemotherapy is frequently chosen to achieve
complete remission and long-term survival, fewer than half of elderly patients receive
treatment and their outcomes remain dismal [5–7]. Conventional chemotherapy treatments
are highly toxic and may increase early death rates in patients 65 and older and these patients
are alternatively given low intensity treatment or palliation only [7, 8]. However, without
treatment, patients succumb to their illness within weeks to months of diagnosis [9].
For medically fit older patients (>60 years), the National Comprehensive Cancer Network
(NCCN) recommend treatment with a combination of an anthracycline and standard dose
cytarabine while for medically unfit older adults with poor physical function or unfavorable
risk disease, the NCCN recommends less intensive chemotherapy with DNA hypomethylating
agents, low-dose cytarabine, or supportive care alone [10]. Allogeneic hematopoietic stem cell
transplantation (HSCT) is rarely used in older patients due to significant comorbidities and
higher risk of transplant-related morbidity and mortality [11, 12]. Even so, data from the
Swedish Acute Leukemia Registry have demonstrated that the majority of patients <80 years
are able to tolerate intensive treatment and have shown benefits in spite of deteriorating organ
function [8, 13].
Elderly, Medicare aged patients constitute the majority of patients with cancer in the United
States, but only 1–2% of them are enrolled in randomized clinical trials (RCTs) providing a
limited evidence base in which to evaluate treatment efficacy and safety in this population [14–
16]. Advanced age or the presence of significant comorbidity was the most frequently cited
factors for clinical trial ineligibility [17]. The incidence of AML is expected to increase due to
the aging population, and given the limited treatment options and clinical trial participation
among the elderly, we examined Medicare beneficiaries diagnosed with AML from a large
population-based cancer registry. The objectives of this analysis were to describe treatment
patterns during the study time period, to examine factors predictive of receiving therapy, and
to identify factors associated with prognosis among older AML patients in real-world clinical
practice.
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2. Methods
2.1. Data sources
Figure 1. Schematic of inclusion/exclusion criteria.
This study utilized linked data from two large population-based data sources of Medicare
beneficiaries with incident cancer identified in the Surveillance, Epidemiology, and End
Results (SEER) program tumor registries. The database contains more than 3.3 million persons
with cancer. Details of the linked SEER-Medicare database have been published elsewhere [18].
Briefly, the database combines clinical, demographic, cancer diagnosis, survival, and cause of
death information with medical claims (hospital, physician, outpatient, home health, and
hospice bills) for adults ≥65 diagnosed with cancer and enrolled in Medicare Part A (inpatient
care, skilled nursing, home healthcare, and hospice care) and Part B (outpatient and physician
services). The SEER is a nationally representative collection of 18 population-based registries
of all incident cancers from diverse geographic areas covering approximately 26% of the US
population. The registries monitor cancer trends, and provide continuous information on
cancer incidence, extent of disease at diagnosis, therapy, and patient survival. A 98% case
ascertainment is mandated with annual quality-assurance studies. The majority of persons
aged 65 years and older in the SEER are successfully matched to their Medicare enrollment
files [18]. All Medicare beneficiaries receive Part A coverage and approximately 95% of
beneficiaries subscribe to Part B. The SEER-Medicare linkage used in this study included all
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Medicare eligible cancer patients appearing in the SEER data through 2009 and their Medicare
claims for Part A and Part B through 2010. Institutional review board approval was waived
because the SEER-Medicare data lack personal identifiers.
2.2. Study cohort
The SEER-Medicare dataset contained 29,857 patients with AML. All patients had microscop‐
ically confirmed AML diagnosis based on the International Classification of Diseases for
Oncology (3rd edition, ICD-O-3) histology codes in the SEER. For inclusion in the study,
patients were restricted to those with a first primary AML in order to exclude therapy-related
AML, diagnosed within the time period from January 1, 2000 to December 31, 2009, ≥66 years
of age, and enrolled in Medicare Parts A and B for a full 12 months before diagnosis date. Study
exclusion criteria were as follows: (1) diagnosis at death, (2) enrollment in a health maintenance
organization (HMO) any time within the 12 months before diagnosis since HMO claims are
unavailable, and (3) receipt of chemotherapy before diagnosis. See Figure 1 for the schematic
of inclusion/exclusion process.
2.3. Study variables
Key study measures include patient demographics (age, race/ethnicity, gender, income, and
education level); clinical characteristics (AML diagnosis, tumor characteristics, risk status,
comorbidity burden, treatment, and survival time). In the absence of cytogenetic data and
molecular abnormalities in the SEER data, prior myelodysplastic syndrome (MDS) or myelo‐
proliferative neoplasm (MPN) was used as a proxy for high-risk patients and was identified
using diagnosis codes in Medicare Parts A and B claim files. MDS or MPN that transforms into
AML are poor prognostic features of the disease and occur more commonly among elderly
patients [19]. Performance status, such as Eastern Cooperative Oncology Group (ECOG), is
not available in the dataset so Medicare claims were used to identify poor performance
indicators (PPI) which include oxygen and related respiratory supplies, wheelchair and
supplies, home health agency services, and skilled nursing facility services occurring in the 12
months before diagnosis [20]. The National Cancer Institute (NCI) comorbidity index [21] is
the gold standard in SEER-Medicare to capture comorbidity burden using diagnosis and
procedure codes to identify the 15 noncancer comorbidities from the Charlson Comorbidity
Index [22] that occurred in the 12 months before cancer diagnosis.
In the Medicare claims files, International Classification of Disease (9th revision) Clinical
Modification (ICD-9-CM) procedure codes were used to identify chemotherapy administra‐
tion while the Healthcare Common Procedural Coding System (HCPCS) “J” codes were used
to identify the specific intravenous chemotherapy administered [23]. The first claim for
chemotherapy had to appear within 3 months of the AML diagnosis date, and patients were
classified into one of three treatment groups using all chemotherapies received during the first
60 days after date of chemotherapy initiation. Those receiving low intensity therapy with a
DNA methyltransferase (DNMT) inhibitor such as Azacitidine or Decitabine were classified
into the hypomethylating agents or “HMA Therapy” group; and those receiving aggressive
induction therapy with Cytarabine + Anthracycline were classified into the “Intensive
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Therapy” group. Given that chemotherapy for AML is usually administered during inpatient
stays, specific chemotherapy agent identification using J codes was not possible in about 70%
of treated patients because inpatient stays are paid according to ICD-9 diagnosis or procedures
codes only. Allogeneic HSCT was also identified using ICD-9-CM and HCPCS codes in the
patient’s Medicare claim files that occurred in the study follow-up period.
2.4. Outcome measures
The primary endpoint was overall survival after the AML diagnosis. Overall survival was
measured from date of diagnosis to date of death. To assess the risk of early death (30-day
mortality and 60-day mortality) after diagnosis, the “treated” group was limited to patients
who received treatment within 30 days after diagnosis to minimize the introduction of
immortal time bias into the analysis (period of follow-up time during which death cannot
occur) [24]. All patients who were still alive at the end of the follow-up period (December 31,
2010) were censored.
2.5. Statistical analysis
Patient characteristics were compared with treatment status and treatment type using the Chi-
square test for categorical variables and ANOVA or t test for continuous variables. We
considered a p-value <0.05 to be statistically significant. Multivariate logistic regression was
used to assess factors associated with receipt of treatment.
In the survival analyses, we made comparisons between the treated and Not Treated patients;
between treated patients receiving HSCT and those who did not; and between HMA Therapy,
Intensive Therapy, and No Treatment groups. The Kaplan-Meier survival analysis was used
to plot survival curves. A time-varying Cox regression model with treatment as a time-
dependent factor was used to account for variation in treatment initiation between groups.
Other independent variables included in the Cox model were selected demographic and
clinical characteristics. All statistical analyses were performed using SAS software, version
9.1.3 (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Treatment patterns
Treatment rates increased over the study time period from 35% in 2000 to 50% in 2009 (Figure
2). Of the 8336 patients who met all study criteria, 3327 (40%) received treatment with
chemotherapy within 3 months of diagnosis and 5009 (60%) did not. As age and comorbidity
burden increased, likelihood of treatment was found to decrease (Figures 3 and 4).
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Figure 2. Treatment status by year of diagnosis.
Figure 3. Treatment status by age.
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Figure 4. Treatment status by comorbidity burden.
3.2. Cohort characteristics and the odds of treatment receipt
Table 1 shows the baseline patient characteristics of the cohort. Overall, the majority of patients
were over 75 years of age (63%), male, white, and married. In the logistic regression model of
factors associated with the odds of not receiving treatment with chemotherapy or HSCT,
increasing age and increasing comorbidity score were confirmed to significantly decrease the
likelihood of receiving treatment. Patients of black or African ancestry were 30% less likely to
receive treatment than white patients. Being widowed, separated/divorced, having a history
of MDS or presence of PPI significantly decreased the likelihood of receiving treatment.
Table 2 shows the baseline patient characteristics by the type of treatment received. Compared
with other treatment groups, patients receiving Intensive Therapy were younger, more likely
male, married, less secondary AML (prior MDS), less likely to have PPIs, and had lower
comorbidity score. Similarities in age, comorbidity burden, and proportion with high-risk
disease were noted in HMA Therapy and Not Treated patients.
Among treated patients, there were 276 (8%) who underwent HSCT therapy and 3051 (92%)
who did not (Table 2). The HSCT patients were younger at diagnosis with a mean age of 73
compared with the non-HSCT group (75 years; p <0.0001) and were more likely to be male.
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Characteristic Total (N = 8336) Odds of no treatment
n % ORa 95% CI p-value
Age at diagnosis
66–70 1322 15.9 ref
71–75 1774 21.3 1.64 1.41–1.91 <0.0001
76–80 1971 23.6 2.86 2.46–3.32 <0.0001
>80 3269 39.2 7.40 6.36–8.61 <0.0001
Sex
Male 4331 52.0 ref
Female 4005 48.0 0.97 0.87–1.07 0.5193
Race/ethnicity
White 7285 87.4 ref
Black 502 6.0 1.30 1.04–1.62 0.0045
Other/unknown 549 6.6 0.87 0.71–1.05 0.4119
Marital status
Married 4373 52.5 ref
Widowed 2492 29.9 1.29 1.13–1.46 0.0036
Separated/divorced 543 6.5 1.34 1.10–1.64 0.0128
Single 535 6.4 1.21 0.99–1.48 0.0796
Unknown 393 4.7 1.31 1.04–1.66 0.0359
Prior MDS
No 6896 82.7 ref
Yes 1440 17.3 1.18 1.03–1.34 0.0151
PPI
No 7280 87.3 ref
Yes 1056 12.7 2.02 1.69–2.41 <0.0001
NCI comorbidity score
0 4266 51.2 ref
1 2104 25.2 1.07 0.95–1.21 0.1017
2 1018 12.2 1.41 1.20–1.66 0.0326
≥3 948 11.4 1.56 1.31–1.86 0.0004
aModel also includes geographic region, income,and year of diagnosis.
Table 1. Factors associated with the odds of NOT receiving chemotherapy or HSCT.
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Characteristic Not
Treated
(N = 5009)
HMA
Therapy
(N = 345)
Intensive Therapy
(N = 124)
p HSCT
(N = 276)
No HSCT
(N = 3051)
p
(%) (%) (%) (%) (%) (%)
Age at diagnosis
66–70 8.8 13.6 39.5 <0.0001 44.6 24.8 <0.0001
71–75 15.9 24.1 31.5 25.4 29.7
76–80 23.3 25.5 16.1 14.5 25.0
>80 51.9 36.8 12.9 15.6 20.5
Sex
Male 49.9 59.1 62.1 0.0002 61.6 54.5 0.0228
Female 50.1 40.9 37.9 38.4 45.5
Race/ethnicity
White 87.2 90.4 87.9 0.2092 88.4 87.6 0.7118
Nonwhite 6.7 9.6 12.1 11.6 12.4
Marital status
Married 46.8 61.2 71.0 <0.0001 59.4 61.1 0.0851
Widowed 35.3 21.4 15.3 18.5 22.1
Separated/divorced 6.5 5.5 13.6a 10.1 6.2
Single 6.4 6.7 7.6 6.4
Unknown 5.1 5.2 4.3 4.2
Prior MDS
No 81.0 79.1 100a 0.0026 88.8 85.0 0.0920
Yes 19.0 20.9 11.2 15.0
PPI
No 83.2 91.3 100a <0.0001 94.2 93.4 0.6245
Yes 16.8 8.7 5.8 6.6
NCI comorbidity score
0 47.3 50.7 55.6 0.1113 55.8 57.2 0.2711
1 25.2 25.8 25.8 22.8 25.5
2 13.8 11.6 18.5a 10.9 9.7
≥3 13.7 11.9 10.5 7.6
aCells with counts of less than 11 are combined in compliance with the National Cancer Institute data in agreement
with small cell sizes.
Table 2. Baseline patient characteristics by type of treatment received.
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3.3. Overall survival by chemotherapy type
Covariates N Totala
(N = 5478)
≤75 yearsa
(N = 1457)
>75 yearsa
(N = 4021)
Treatment HR 95% CI HR 95% CI HR 95% CI
Not treated (ref) 5009
HMA therapy 345 0.52 0.47–0.59 0.54 0.45–0.66 0.50 0.44–0.58
Intensive therapy 124 0.33 0.27–0.41 0.30 0.23–0.39 0.38 0.26–0.54
Age at diagnosis
66–70 (ref) 537
71–75 920 1.31 1.17–1.46
76–80 1276 1.42 1.27–1.58
>80 2745 1.68 1.52–1.86
Sex
Male (ref) 2780
Female 2698 1.01 0.96–1.08 0.99 0.88–1.11 1.03 0.96–1.10
Race/ethnicity
White (ref) 4788
Black 350 0.96 0.86–1.07 1.04 0.85–1.28 0.92 0.80–1.05
Other/unknown 340 0.89 0.79–1.00 0.93 0.74–1.16 0.86 0.75–0.98
Marital status
Married (ref) 2644
Widowed 1859 1.12 1.05–1.20 1.33 1.14–1.56 1.10 1.02–1.19
Separated/divorced 349 1.11 0.99–1.25 1.09 0.89–1.33 1.07 0.93–1.23
Single 349 1.18 1.05–1.32 1.31 1.07–1.59 1.12 0.97–1.28
Unknown 277 1.00 0.88–1.13 0.94 0.73–1.20 1.01 0.87–1.18
Prior MDS
No (ref) 4445
Yes 1033 0.97 0.91–1.04 1.03 0.89–1.19 0.95 0.88–1.03
PPI
No (ref) 4605
Yes 873 1.30 1.20–1.40 1.58 1.32–1.90 1.26 1.16–1.38
NCI comorbidity score
0 (ref) 2611
1 1383 1.18 1.10–1.26 1.35 1.18–1.54 1.12 1.03–1.21
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Covariates N Totala
(N = 5478)
≤75 yearsa
(N = 1457)
>75 yearsa
(N = 4021)
Treatment HR 95% CI HR 95% CI HR 95% CI
2 749 1.29 1.19–1.41 1.43 1.20–1.70 1.25 1.14–1.38
≥3 735 1.38 1.26–1.51 1.40 1.16–1.69 1.35 1.21–1.49
aModel also includes geographic region, income, and year of diagnosis.
Table 3. Adjusted overall survival by treatment type.
Patients receiving Intensive Therapy had longer unadjusted median overall survival (18.9
months) compared with patients receiving HMA Therapy (6.6 months) and those Not Treated
(1.5 months; log rank p <0.0001). In the multivariable survival analysis (Table 3), significantly
lower risks of death were noted among patients treated with Intensive Therapy and HMA
Therapy compared with Not Treated with similar mortality risk reductions maintained in the
younger (≤75) and older (>75) cohorts. Other factors found to be predictive of mortality include
increasing age, increasing comorbidity score, and presence of PPIs.
3.4. Overall survival by HSCT
The unadjusted median overall survival was significantly higher for the HSCT (9.7 months)
compared with the non-HSCT group (4.7 months; log rank p < 0.0001) and this survival benefit
was supported in the multivariable survival analysis (Table 4), where a statistically significant,
21% lower risk of death in the HSCT group was found compared with the non-HSCT group.
Stratifying by age, the lower risk of death among the HSCT group was only supported in the
younger cohort (≤75 years old).
Treatment Treateda(N = 3321) ≤75 yearsa
(N = 1854)
>75 yearsa
(N = 1467)
HR 95% CI p HR 95% CI p HR 95% CI p
No HSCT (ref)
HSCT 0.80 0.70–0.92 0.0015 0.63 0.53–0.75 <0.0001 1.21 0.96–1.53 0.1041
aAdjusted for age, sex, race, marital status, geographic region, income, year of diagnosis, prior MDS, PPI, and NCI
comorbidity index.
Table 4. Adjusted overall survival among treated patients with and without HSCT.
4. Discussion
Treatment for elderly patients diagnosed with AML has increased over time from the 34%
reported by Lang et al. between 1991 and 2001 [7] to the 40% reported in our study between
2000 and 2010. However, the 60% of elderly AML patients who remain untreated following
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diagnosis represents a large unmet need in this patient population. We observed a significant
survival benefit with receiving antileukemic therapy even among the HMA Therapy group
who had similar characteristics to the untreated group. Our multivariate analysis demonstrat‐
ed a greater reduction in mortality among patients receiving Intensive Therapy compared with
HMA Therapy, but both therapeutic options appeared to be equally better than supportive
measures when the cohorts were properly matched for relevant confounders. Results from
prior RCTs also support our findings and have demonstrated not only an improvement in
complete remission rate, but also an improvement in overall survival for AML patients aged
65 years or older treated with intensive chemotherapy [25] and HMA Therapy [26] compared
with supportive measures only.
The current results also draw attention to the perception that elderly AML is an untreatable
disease and conventional chemotherapy is usually withheld due to toxicity and high early
death rates. Our results, however, confirm findings from other registry-based analyses that
showed elderly AML patients who received treatment exhibited a lower early death rate
compared with untreated patients or palliation after adjustment for confounding factors [8,
13, 27]. Despite the overall improvement in early death rates in the treated versus untreated
groups, subsets of patients older than 80 years or those with poor performance or higher
comorbidity burden did experience higher risks of early death suggesting caution in use of
therapy within these subgroups.
The HSCT therapy was associated with a significant lower risk of death compared with
patients receiving chemotherapy only and the survival benefit was even more pronounced in
the younger cohort (≤75 years) with no benefit in the >75 years old subset. Although our
observations are at best hypothesis generating, they raise the question of whether allogeneic
HSCT provides therapeutic benefit to AML patients older than 75 years of age. Although use
of myeloablative allogeneic HSCT is rare among older unfit patients, reduced-intensity
conditioning (RIC) of the allogeneic HSCT has shown encouraging results in the postremission
setting [11, 12, 28] and is considered an additional treatment option after complete response
from induction therapy among older patients ≥60 years [10]. In fact, a recent uncontrolled study
demonstrated that reduced-intensity conditioning HSCT as postremission therapy was well
tolerated in selected older patients with AML, and survival compared favorably to historical
patients treated without HSCT [29]. However, in the “real world,” chronologic age remains a
driving factor in receiving HSCT as only 8% of patients in the current study who received
chemotherapy underwent subsequent HSCT therapy. The randomized clinical trials are
needed to define the role of allogeneic HSCT as postremission therapy in this cohort of patients.
The results show that patients receiving Intensive Therapy were younger, had less secondary
AML, were less likely to have indicators of poor performance, and had lower comorbidity
burden compared with patients receiving HMA Therapy and No Treatment, and this may be
related to physician beliefs that elderly patients are less able to tolerate more aggressive
treatments [5, 30–32]. Undertreatment because of age, independent of comorbidities, occurs in
other oncology studies, and may be due to patient preferences, physicians’ tendencies to treat
patients according to their chronologic age, and a lack of evidence-based guidelines for treating
older patients [33, 34]. In two prior RCTs where preselection of conventional care regimens
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was performed before subjects were randomized, those assigned to aggressive therapies had
a median of 5–8 years younger than their counterparts assigned to less intensive regimens [35,
36]. These age disparities in treatment patterns are associated with higher mortality in older
AML patients [5, 6] and our results provide further support that demographic factors such as
age should not discourage the use of guideline-recommended therapies.
Treatment receipt also varied by gender, socioeconomic factors, geographic region, and marital
status, similar to patterns observed in prior oncology research [37–39]. Even after adjustment
for known confounders, married patients were more likely to receive treatment and had better
outcomes compared with unmarried patients [39] and may indicate that marital status is a
surrogate of social-economic support in this patient population. Reducing the disparity of
nonclinical factors such as income and geographic region on receipt of cancer therapy may
reduce the adverse impact on outcomes among these patients. Further research is warranted
to better quantify how nonclinical factors contribute to receipt of cancer therapy and outcomes.
4.1. Strengths and limitations
This unique dataset allowed us to examine all AML patients, both treated and untreated, and
provided insight into treatment decisions and effectiveness of therapies in routine oncology
practice among this underrepresented elderly patient population. Our analysis has several
strengths including the large sample size from a population-based cancer registry, the diverse
geographic representation of AML patients in the United States, and comprehensive, longi‐
tudinal data with medical claims from the time a person is eligible for Medicare until death
regardless of residence or service area.
However, there are some limitations to the analysis that deserve mention. The SEER registry
does not collect baseline molecular and cytogenetic information or performance status, and
these factors influence clinicians’ decisions to treat or the specific regimen to administer. Our
proxies for stage (including claims for prior MDS as a marker of disease severity) and per‐
formance status (including claims to identify indicators of poor performance) may not
adequately assess stage or performance status in all patients and may be subject to bias.
The results of the comparative effectiveness analysis should be interpreted with caution due
to the large amount of missing data and resulting small sample size of treatment groups.
Conventional chemotherapy treatments for AML are highly toxic [9] and generally require
inpatient treatment. Inpatient stays are paid based on ICD-9 diagnosis or procedures codes
only and not the specific chemotherapy J code administered. Therefore, we were unable to
define the type of chemotherapy received for 70% of the treated cohort without the specific J
code. Given that induction chemotherapy with curative intent in the outpatient setting is
applied to very select elderly AML patients, our findings may not be representative of the
general patient population receiving intensive induction therapy.
Finally, this analysis does not contain information regarding treatment patterns and outcomes
of patients enrolled in HMO plans as these claims are not submitted to Medicare. Prior solid
tumor studies found that HMO enrollees were diagnosed earlier and had better overall
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survival compared with fee-for-service (FFS) plan members [40, 41]. An investigation of how
patient characteristics, treatment patterns, and prognosis may differ between these alternative
healthcare plans and Medicare enrollees would be a productive area for additional evaluation.
In conclusion, our findings provide an important context for therapeutic selection that occurs
in older patients with AML and suggests that age alone should not discourage the use of
guideline-recommended therapies particularly because of the high disparities in outcomes
between treatment receipt and palliative care. But even with treatment, outcomes remain
dismal, and given this important unmet medical need, many new agents are currently in
development for older patients with AML [42–45]. Moving forward, it will be important to
identify patients less likely to be treated at diagnosis and design clinical trials to address the
therapeutic challenges that exist in this cohort of patients.
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